Litigation
Pharmacia Corporation et al. v. Par Pharmaceutical, Inc.
judgment affirmed on appeal01-6011; 04-1478; 04-1496
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Court
- U.S. District Court for the District of New Jersey; U.S. Court of Appeals for the Federal Circuit
- Filed
- 2001-12-21
- Terminated
- 2005-08-10
Patents at issue (3)
Plaintiffs (5)
Defendants (1)
Summary
ANDA litigation after Par's Paragraph IV notice concerning Xalatan/latanoprost. The District of New Jersey found the '368 patent unenforceable for inequitable conduct but upheld the '504 patent; the Federal Circuit affirmed. Narrative states the patents actually asserted were U.S. 5,422,368 and U.S. 5,296,504, not 6,030,999.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).